| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1042213744 |
| P356 | DOI | 10.1038/NRMICRO2090 |
| P932 | PMC publication ID | 2750777 |
| P698 | PubMed publication ID | 19198616 |
| P5875 | ResearchGate publication ID | 23986117 |
| P50 | author | Shuwen Liu | Q87852411 |
| Shibo Jiang | Q88118974 | ||
| Lanying Du | Q89375433 | ||
| Yusen Zhou | Q98175621 | ||
| P2093 | author name string | Bo-Jian Zheng | |
| Yuxian He | |||
| P2860 | cites work | CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus | Q24307914 |
| Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats | Q24536078 | ||
| pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN | Q24563490 | ||
| Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus | Q28188496 | ||
| A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2 | Q28191005 | ||
| Coronavirus as a possible cause of severe acute respiratory syndrome | Q28200848 | ||
| Characterization of a novel coronavirus associated with severe acute respiratory syndrome | Q28202401 | ||
| HIV entry and its inhibition | Q28273919 | ||
| Bats are natural reservoirs of SARS-like coronaviruses | Q28274751 | ||
| Structural characterization of the SARS-coronavirus spike S fusion protein core. | Q48009341 | ||
| Laboratory-acquired SARS raises worries on biosafety | Q48020374 | ||
| DNA vaccine of SARS-Cov S gene induces antibody response in mice | Q48029320 | ||
| Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. | Q51660929 | ||
| SARS-Associated Coronavirus | Q51673467 | ||
| Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. | Q51803005 | ||
| Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. | Q52570591 | ||
| Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. | Q52571074 | ||
| The intracellular sites of early replication and budding of SARS-coronavirus | Q56877432 | ||
| Severe acute respiratory syndrome--retrospect and lessons of 2004 outbreak in China | Q57101917 | ||
| A model of the ACE2 structure and function as a SARS-CoV receptor. | Q64924413 | ||
| Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model | Q79340070 | ||
| Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse | Q79426388 | ||
| Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses | Q80818723 | ||
| Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines | Q81481051 | ||
| Solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 domain in the prefusion state | Q82685553 | ||
| Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor | Q82697155 | ||
| A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity | Q83157114 | ||
| SARS-CoV, but not HCoV-NL63, utilizes cathepsins to infect cells: viral entry | Q40220808 | ||
| Proteolysis of SARS-associated coronavirus spike glycoprotein | Q40220881 | ||
| Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines | Q40263910 | ||
| Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus. | Q40330912 | ||
| SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells | Q40341738 | ||
| Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines | Q40411117 | ||
| Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus | Q40416852 | ||
| Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein | Q40436586 | ||
| Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies | Q40437929 | ||
| Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. | Q40471278 | ||
| Silencing of SARS-CoV spike gene by small interfering RNA in HEK 293T cells | Q40500164 | ||
| Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine | Q40506063 | ||
| An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus | Q40508602 | ||
| A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice | Q40520942 | ||
| Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus | Q40534160 | ||
| Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein | Q40548165 | ||
| S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients | Q40551623 | ||
| Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference | Q40585048 | ||
| Short interfering RNA confers intracellular antiviral immunity in human cells | Q40721804 | ||
| Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide | Q42407073 | ||
| Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design | Q42424192 | ||
| HIV-1 inhibition by a peptide | Q42559777 | ||
| Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. | Q42612038 | ||
| Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents | Q42716746 | ||
| Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. | Q42844863 | ||
| Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy. | Q43218942 | ||
| SARS virus returns to China as scientists race to find effective vaccine | Q43240810 | ||
| Infectious diseases. Mounting lab accidents raise SARS fears | Q44274438 | ||
| Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level | Q44282477 | ||
| A patient with asymptomatic severe acute respiratory syndrome (SARS) and antigenemia from the 2003-2004 community outbreak of SARS in Guangzhou, China | Q44668500 | ||
| Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry | Q45141976 | ||
| Inhibition of SARS-CoV replication by siRNA. | Q45206542 | ||
| Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. | Q45262795 | ||
| siRNA targeting the leader sequence of SARS-CoV inhibits virus replication. | Q45496781 | ||
| Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets | Q45501850 | ||
| Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. | Q45622393 | ||
| Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways | Q45640664 | ||
| Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors | Q45659807 | ||
| Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets | Q47283945 | ||
| The SARS-CoV S glycoprotein: expression and functional characterization | Q47346882 | ||
| Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). | Q47736945 | ||
| A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2. | Q47774466 | ||
| Evaluation by indirect immunofluorescent assay and enzyme linked immunosorbent assay of the dynamic changes of serum antibody responses against severe acute respiratory syndrome coronavirus. | Q47827023 | ||
| Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. | Q47924234 | ||
| Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core | Q47932220 | ||
| Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection | Q47939183 | ||
| An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus | Q47957009 | ||
| Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection | Q28369033 | ||
| Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants | Q28764574 | ||
| Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China | Q29618055 | ||
| The Genome sequence of the SARS-associated coronavirus | Q29619007 | ||
| Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. | Q30230264 | ||
| Severe acute respiratory syndrome (SARS): a year in review. | Q30350011 | ||
| Obstacles and advances in SARS vaccine development. | Q30351493 | ||
| Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection | Q30447031 | ||
| B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein | Q31149856 | ||
| The life cycle of SARS coronavirus in Vero E6 cells | Q33203307 | ||
| The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cells | Q33207348 | ||
| Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus | Q33210858 | ||
| Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. | Q33223061 | ||
| Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody | Q33239031 | ||
| Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites in different epidemic groups | Q33259340 | ||
| Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase | Q33266597 | ||
| Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus. | Q33267285 | ||
| A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice | Q33269158 | ||
| Structural basis for membrane fusion by enveloped viruses | Q33637921 | ||
| Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice | Q33696283 | ||
| Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses | Q33756740 | ||
| Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants | Q33780455 | ||
| Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein | Q33788831 | ||
| Antibodies in the therapy of colon cancer. | Q33800949 | ||
| Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. | Q33834543 | ||
| Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry | Q33920306 | ||
| Pathology and pathogenesis of severe acute respiratory syndrome | Q34003202 | ||
| Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus | Q34193942 | ||
| Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. | Q34376025 | ||
| An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies | Q34437463 | ||
| Structure of SARS coronavirus spike receptor-binding domain complexed with receptor | Q34451350 | ||
| Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters | Q34490759 | ||
| Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain | Q34717693 | ||
| Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus | Q35085075 | ||
| SARS coronavirus: a new challenge for prevention and therapy | Q35143451 | ||
| Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV) | Q35740733 | ||
| Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus | Q35857387 | ||
| Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China | Q35880772 | ||
| Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies | Q35901171 | ||
| Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice | Q35914462 | ||
| Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus | Q35953179 | ||
| From genome to antivirals: SARS as a test tube. | Q36062699 | ||
| Immunological responses against SARS-coronavirus infection in humans. | Q36280532 | ||
| Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry | Q36315018 | ||
| Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway | Q36424025 | ||
| Amino acid substitutions in the S2 subunit of mouse hepatitis virus variant V51 encode determinants of host range expansion | Q36424092 | ||
| Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity | Q36449078 | ||
| Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge | Q36498144 | ||
| SARS coronavirus and innate immunity | Q36539000 | ||
| Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity | Q36572218 | ||
| Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association | Q36602721 | ||
| Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein | Q36634787 | ||
| HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds | Q36725249 | ||
| A review of studies on animal reservoirs of the SARS coronavirus | Q36798770 | ||
| Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus | Q36845879 | ||
| Pathogenetic mechanisms of severe acute respiratory syndrome. | Q36934231 | ||
| Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice | Q37010921 | ||
| Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. | Q37011150 | ||
| Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against | Q37015424 | ||
| Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry | Q37356916 | ||
| Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor | Q37423228 | ||
| Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells | Q37567824 | ||
| Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets | Q37596935 | ||
| Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine | Q38310521 | ||
| Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque | Q39362979 | ||
| Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E. | Q39700192 | ||
| Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine | Q39987729 | ||
| A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV. | Q40073664 | ||
| Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted | Q40128591 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| SARSr-CoV | Q278567 | ||
| SARS-CoV-1 | Q85438966 | ||
| P304 | page(s) | 226-236 | |
| P577 | publication date | 2009-02-09 | |
| 2009-03-01 | |||
| P1433 | published in | Nature Reviews Microbiology | Q1071797 |
| P1476 | title | The spike protein of SARS-CoV--a target for vaccine and therapeutic development | |
| P478 | volume | 7 |
| Q107032002 | 3-Hydroxyphthalic Anhydride-Modified Chicken Ovalbumin as a Potential Candidate Inhibits SARS-CoV-2 Infection by Disrupting the Interaction of Spike Protein With Host ACE2 Receptor |
| Q33904997 | A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity |
| Q96110341 | A Mouse Model of SARS-CoV-2 Infection and Pathogenesis |
| Q98178351 | A Perspective on Emerging Therapeutic Interventions for COVID-19 |
| Q97519840 | A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS |
| Q33743790 | A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. |
| Q35972651 | A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide |
| Q34135057 | A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2. |
| Q64374803 | A highly immunogenic, protective and safe adenovirus-based vaccine expressing MERS-CoV S1-CD40L fusion protein in transgenic human DPP4 mouse model |
| Q95851276 | A human neutralizing antibody targets the receptor binding site of SARS-CoV-2 |
| Q30379384 | A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. |
| Q27490484 | A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo |
| Q89046119 | A new threat from an old enemy: Re‑emergence of coronavirus (Review) |
| Q94670272 | A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 |
| Q36615939 | A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. |
| Q98222221 | A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2 |
| Q46374737 | A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. |
| Q37152873 | A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV |
| Q41272962 | A small region of porcine hemagglutinating encephalomyelitis virus spike protein interacts with the neural cell adhesion molecule |
| Q38275790 | A structural view of coronavirus-receptor interactions |
| Q35063993 | A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines |
| Q91934668 | ADAM17 inhibition may exert a protective effect on COVID-19 |
| Q92138204 | Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies |
| Q98623661 | An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques |
| Q34539529 | An eight-year epidemiologic study based on baculovirus-expressed type-specific spike proteins for the differentiation of type I and II feline coronavirus infections. |
| Q89470675 | An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies |
| Q38043556 | Animal models in virus research: their utility and limitations |
| Q30352512 | Anti-SARS coronavirus agents: a patent review (2008 - present). |
| Q38631970 | Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway |
| Q84315455 | Antibodies and vaccines against Middle East respiratory syndrome coronavirus |
| Q44998852 | Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. |
| Q39526647 | Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. |
| Q37361159 | Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells |
| Q90674928 | Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? |
| Q97886695 | Association between COVID-19 and cardiovascular disease |
| Q107473208 | Biochemical evidence of furin specificity and potential for phospho-regulation at Spike protein S1/S2 cleavage site in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV |
| Q97636279 | COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives |
| Q97518345 | COVID-19 and the Chemical Senses: Supporting Players Take Center Stage |
| Q91945830 | COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies |
| Q90425437 | COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics |
| Q99419015 | COVID-19: Current status, Challenges and Future Perspectives |
| Q91717735 | COVID-19: Risk Groups, Mechanistic Insights, and Challenges |
| Q90744942 | COVID-19: what has been learned and to be learned about the novel coronavirus disease |
| Q51716894 | Calling for rapid development of a safe and effective MERS vaccine. |
| Q93188504 | Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2? |
| Q94589965 | Cell entry mechanisms of SARS-CoV-2 |
| Q33552505 | Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection |
| Q102058982 | Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys |
| Q90589863 | Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine |
| Q97086302 | Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review |
| Q107134863 | Coiled-coil heterodimers with increased stability for cellular regulation and sensing SARS-CoV-2 spike protein-mediated cell fusion |
| Q41967852 | Comparative analysis of the activation of unfolded protein response by spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus HKU1. |
| Q34201227 | Computer aided prediction and identification of potential epitopes in the receptor binding domain (RBD) of spike (S) glycoprotein of MERS-CoV. |
| Q52595409 | Contribution of porcine aminopeptidase N to porcine deltacoronavirus infection. |
| Q98735592 | Contriving Multi-Epitope Subunit of Vaccine for COVID-19: Immunoinformatics Approaches |
| Q94539926 | Convalescent plasma in Covid-19: Possible mechanisms of action |
| Q96225284 | Corona virus versus existence of human on the earth: A computational and biophysical approach |
| Q92076061 | Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children |
| Q92102904 | Coronavirus as silent killer: recent advancement to pathogenesis, therapeutic strategy and future perspectives |
| Q90322109 | Coronavirus disease 2019: What we know? |
| Q99402735 | Coronavirus infections in children: from SARS and MERS to COVID-19, a narrative review of epidemiological and clinical features |
| Q91766933 | Coronavirus membrane fusion mechanism offers as a potential target for antiviral development |
| Q95602418 | Coronaviruses pandemics: Can neutralizing antibodies help? |
| Q30393364 | Crucial steps in the structure determination of a coronavirus spike glycoprotein using cryo-electron microscopy |
| Q97587517 | Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein |
| Q46274625 | Cryo-EM structure of porcine delta coronavirus spike protein in the pre-fusion state |
| Q30845557 | Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains |
| Q27314711 | Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer |
| Q40397876 | Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding |
| Q27012578 | Current advancements and potential strategies in the development of MERS-CoV vaccines |
| Q94589199 | Current development of COVID-19 diagnostics, vaccines and therapeutics |
| Q37921384 | Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles |
| Q40061001 | Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review |
| Q30400066 | DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice |
| Q107343965 | Deletion of ER-retention motif on SARS-CoV-2 spike protein reduces cell hybrid during cell–cell fusion |
| Q107073656 | Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays |
| Q94588639 | Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 |
| Q94469287 | Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza |
| Q56156866 | Development of SARS vaccines and therapeutics is still needed |
| Q44106409 | Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses |
| Q34432011 | Development, characterization, and application of monoclonal antibodies against severe acute respiratory syndrome coronavirus nucleocapsid protein |
| Q98891841 | Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk |
| Q34983662 | Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses |
| Q98906660 | Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19 |
| Q97642571 | Distinct conformational states of SARS-CoV-2 spike protein |
| Q90576464 | Drug targets for corona virus: A systematic review |
| Q103028535 | Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19 |
| Q107143917 | Dysregulation of Cell Signaling by SARS-CoV-2 |
| Q90004418 | Early transmission patterns of coronavirus disease 2019 (COVID-19) in travellers from Wuhan to Thailand, January 2020 |
| Q34594139 | Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness |
| Q89613924 | Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments |
| Q98626411 | Emerging strategies on in silico drug development against COVID-19: challenges and opportunities |
| Q100430770 | Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice |
| Q90617531 | Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2 |
| Q100749460 | Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches |
| Q96308456 | Focus on a 2019-novel coronavirus (SARS-CoV-2) |
| Q61818478 | From SARS to MERS, Thrusting Coronaviruses into the Spotlight |
| Q95298068 | From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development |
| Q42282766 | Full genome analysis of a novel type II feline coronavirus NTU156. |
| Q38252639 | Functional nanomaterials can optimize the efficacy of vaccines |
| Q35801839 | Functional transcriptional regulatory sequence (TRS) RNA binding and helix destabilizing determinants of murine hepatitis virus (MHV) nucleocapsid (N) protein. |
| Q97551111 | Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges |
| Q51771976 | Generating stable chinese hamster ovary cell clones to produce a truncated SARS‐CoV spike protein for vaccine development |
| Q95617512 | Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses |
| Q91706263 | Genotype and phenotype of COVID-19: Their roles in pathogenesis |
| Q27728036 | Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy |
| Q107344131 | Glycosylation is a key in SARS-CoV-2 infection |
| Q99711258 | Harnessing Memory NK Cell to Protect Against COVID-19 |
| Q96647308 | Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection |
| Q38667715 | Host Factors in Coronavirus Replication |
| Q99201268 | How can nanotechnology help to combat COVID-19? Opportunities and urgent need |
| Q34491357 | Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing |
| Q38098075 | Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1. |
| Q95851279 | Human neutralizing antibodies elicited by SARS-CoV-2 infection |
| Q96647310 | Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art |
| Q94938624 | Identification of Human Single-Domain Antibodies against SARS-CoV-2 |
| Q101222456 | Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells |
| Q94672026 | Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2 |
| Q30951751 | Identification of a novel conserved HLA-A*0201-restricted epitope from the spike protein of SARS-CoV. |
| Q30432706 | Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development |
| Q36760764 | Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates |
| Q41752133 | Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice |
| Q89542206 | Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV |
| Q99608160 | In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations |
| Q36154930 | Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus |
| Q39095556 | Influence of hydrophobic and electrostatic residues on SARS-coronavirus S2 protein stability: insights into mechanisms of general viral fusion and inhibitor design |
| Q34009523 | Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans |
| Q30359335 | Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. |
| Q37434385 | Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines |
| Q95269110 | Investigating the genomic landscape of novel coronavirus (2019-nCoV) to identify non-synonymous mutations for use in diagnosis and drug design |
| Q55463226 | Investigation of Antibody-Dependent Enhancement (ADE) of SARS coronavirus infection and its role in pathogenesis of SARS. |
| Q30235867 | Jumping species-a mechanism for coronavirus persistence and survival |
| Q100387986 | KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney |
| Q89542749 | Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV |
| Q100694566 | Learning from the past: development of safe and effective COVID-19 vaccines |
| Q92083752 | MERS Coronavirus: An Emerging Zoonotic Virus |
| Q60813078 | MERS – A cautionary tale |
| Q30248743 | MERS-CoV spike protein: Targets for vaccines and therapeutics |
| Q30240139 | MERS-CoV spike protein: a key target for antivirals |
| Q34176466 | Metabolomics - a useful tool for prediction of protein production and processing? |
| Q64069097 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development |
| Q61814884 | Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism |
| Q30432264 | Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread |
| Q42249511 | Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies |
| Q26796501 | Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control |
| Q37143501 | Middle East respiratory syndrome vaccines |
| Q95272052 | Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2 |
| Q42152380 | Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. |
| Q100737088 | Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2 |
| Q89820495 | Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity |
| Q98157481 | Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19 |
| Q91578226 | Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses |
| Q37929687 | Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential |
| Q91912173 | Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels |
| Q94551879 | Novel Coronavirus Polymerase and Nucleotidyl-transferase Structures: Potential to Target New Outbreaks |
| Q90538321 | Novel Coronavirus: What Neuroradiologists as Citizens of the World Need to Know |
| Q111537797 | Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain |
| Q114868908 | Open Science Resources for the Mass Spectrometry-Based Analysis of SARS-CoV-2 |
| Q30401512 | Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate |
| Q99624588 | Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine |
| Q37188934 | Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection |
| Q41965287 | Pathogenesis of neurotropic murine coronavirus is multifactorial |
| Q50131822 | Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains. |
| Q93190302 | Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 |
| Q97592236 | Planning for COVID-19 vaccines safety surveillance |
| Q34332142 | Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients |
| Q35159147 | Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein |
| Q100384122 | Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review |
| Q94549050 | Potential Applications of Plant Biotechnology against SARS-CoV-2 |
| Q97067433 | Potential of SARS-CoV-2 to Cause CNS Infection: Biologic Fundamental and Clinical Experience |
| Q37767654 | Potential of carbohydrate-binding agents as therapeutics against enveloped viruses |
| Q99406885 | Potential use of polyphenols in the battle against COVID-19 |
| Q47210194 | Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference |
| Q98730822 | Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development |
| Q57172187 | Prospects for a MERS-CoV spike vaccine |
| Q40744757 | Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice |
| Q99728288 | Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay |
| Q103027776 | RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response |
| Q100763479 | Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2 |
| Q35943657 | Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence |
| Q97518859 | Reappearance of effector T cells is associated with recovery from COVID-19 |
| Q64118341 | Recent Aspects on the Pathogenesis Mechanism, Animal Models and Novel Therapeutic Interventions for Middle East Respiratory Syndrome Coronavirus Infections |
| Q39727842 | Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy |
| Q35033862 | Receptor binding domain based HIV vaccines. |
| Q35115572 | Receptor recognition mechanisms of coronaviruses: a decade of structural studies |
| Q30353170 | Receptor-binding domain as a target for developing SARS vaccines. |
| Q30399700 | Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection |
| Q26851979 | Receptor-binding domain-based subunit vaccines against MERS-CoV |
| Q99608352 | Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2 |
| Q36779713 | Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. |
| Q37366744 | Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity |
| Q35815644 | Reconstitution of the receptor-binding motif of the SARS coronavirus |
| Q98771893 | Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review |
| Q99711236 | Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19 |
| Q90748419 | Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases |
| Q97430314 | Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review |
| Q36650501 | Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome |
| Q96342886 | Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein |
| Q100464708 | SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients |
| Q102131196 | SARS-CoV-2 nucleocapsid protein phase-separates with RNA and with human hnRNPs |
| Q96642691 | SARS-CoV-2 nucleocapsid protein undergoes liquid-liquid phase separation stimulated by RNA and partitions into phases of human ribonucleoproteins |
| Q109295321 | SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro |
| Q34324907 | Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design |
| Q93230276 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response |
| Q64374628 | Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection |
| Q39677274 | Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection |
| Q95603898 | Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins |
| Q27675849 | Solution Structure of Mouse Hepatitis Virus (MHV) nsp3a and Determinants of the Interaction with MHV Nucleocapsid (N) Protein |
| Q91807337 | Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 |
| Q90738246 | Structural basis of receptor recognition by SARS-CoV-2 |
| Q27678981 | Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 |
| Q38825332 | Structure of the S1 subunit C-terminal domain from bat-derived coronavirus HKU5 spike protein |
| Q36373305 | Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. |
| Q33897964 | Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody |
| Q99575736 | Substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2 circulating in South America |
| Q91711469 | Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses |
| Q40566186 | Synthetic virus-like particles prepared via protein corona formation enable effective vaccination in an avian model of coronavirus infection |
| Q41242033 | Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus |
| Q30241347 | T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. |
| Q102369251 | Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions |
| Q97676079 | Targeting SARS-CoV-2 RBD interface: a supervised computational data-driven approach to identify potential modulators |
| Q88485680 | The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus |
| Q98171290 | The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity |
| Q99561915 | The Inhibitory Effect of a Coronavirus Spike Protein Fragment with ACE2 |
| Q34652511 | The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents |
| Q41922286 | The bulky and the sweet: How neutralizing antibodies and glycan receptors compete for virus binding |
| Q103002692 | The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection |
| Q33934034 | The emergence of the Middle East respiratory syndrome coronavirus |
| Q98200267 | The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19 |
| Q98217818 | The importance of cell-mediated immunity in COVID-19 - An opinion |
| Q33614533 | The minor envelope glycoproteins GP2a and GP4 of porcine reproductive and respiratory syndrome virus interact with the receptor CD163. |
| Q93230756 | The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases? |
| Q90482703 | The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines |
| Q92130769 | The potential danger of suboptimal antibody responses in COVID-19 |
| Q38171580 | The receptor binding domain of MERS-CoV: the dawn of vaccine and treatment development |
| Q100512389 | The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV |
| Q98936342 | Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to |
| Q37169882 | Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015. |
| Q64360051 | Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: A computer-aided vaccine design approach |
| Q34339544 | US-like strain of porcine epidemic diarrhea virus outbreaks in Taiwan, 2013-2014. |
| Q38819802 | Understanding bat SARS-like coronaviruses for the preparation of future coronavirus outbreaks - Implications for coronavirus vaccine development |
| Q99712067 | Unraveling the Epidemiology, Geographical Distribution, and Genomic Evolution of Potentially Lethal Coronaviruses (SARS, MERS, and SARS CoV-2) |
| Q97592234 | Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus |
| Q99604172 | Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system |
| Q93199923 | Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains |
| Q38778044 | Vaccines for the prevention against the threat of MERS-CoV. |
| Q95627691 | Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Alum Induces Protective Immunity and Reduces Immune Enhancement |
| Q100514972 | Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement |
| Q30218075 | Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate |
Search more.